FRANKLIN LAKES, N.J. (June 1, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that Laura Boros has been named president of Pharmaceutical Systems (PS), effective today.

Boros will be responsible for driving global strategic, operational and commercial performance of the PS business unit and will report to Mike Garrison, executive vice president (EVP) and president of the Medical segment. Boros succeeds Eric Borin, who was named to president of Medication Delivery Solutions (MDS) in late 2022. Since 2020, Boros has served as senior vice president of global nutrition at Reckitt, a leader in hygiene, health and nutrition brands. 

“Laura has more than 25 years of progressive leadership experience and is uniquely suited to lead PS, one of BD’s highest growth businesses,” said Garrison. “Her global experience, coupled with her track record of driving innovation across the healthcare and consumer industries, will support the next generation of PS growth as it continues to enhance the delivery of medications for the pharmaceutical industry and patients around the world.”

Boros started her career at Procter & Gamble in various country, regional and global roles before joining Hertz as regional vice president for Europe. She then held leadership positions within the pharmaceutical industry at both Novartis and GlaxoSmithKline in high-growth categories. Most recently, she led the global nutrition business at Reckitt and oversaw several strategic M&A projects for the company. She holds a Master of Electrical Engineering degree from Politehnica University in Bucharest, Romania and a Master of Business Administration from Emory Business School in Atlanta, Georgia.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.